文献速递药物不良反应与药物警戒特殊人群用药

门诊成人用磺胺甲噁唑-甲氧苄啶的安全性:系统综述与荟萃分析及药物警戒分析

Safety of sulfamethoxazole-trimethoprim for the treatment of bacterial infection in outpatient settings: A systematic review and meta-analysis with active comparator disproportionality analysis.
PubMed 文献 · Br J Clin Pharmacol · 2025-03-24

该系统综述与荟萃分析纳入43项研究,比较成人门诊使用磺胺甲噁唑-甲氧苄啶(SMX-TMP)与其他抗生素的不良事件风险,发现SMX-TMP皮疹风险约为其他抗生素的2.56倍(95%CI 1.69-3.89)。药物警戒数据进一步显示其皮肤及血液系统等不良事件报告频率更高。

要点

  • SMX-TMP皮疹风险显著高于其他抗生素,合并RR为2.56(95%CI 1.69-3.89)。
  • 药物警戒数据显示SMX-TMP相比阿奇霉素,Stevens-Johnson综合征报告增加5倍。
  • SMX-TMP还显示全血细胞减少、中性粒细胞减少及高钾血症等报告频率升高。

核心结论

  • 荟萃分析与药物警戒研究提示,SMX-TMP相比其他抗生素(包括阿莫西林/克拉维酸、阿奇霉素和呋喃妥因)与更高的不良事件风险相关。

研究设计与样本

  • 系统综述与荟萃分析检索MEDLINE和Embase至2024年8月12日,纳入比较成人门诊使用SMX-TMP与其他抗生素后不良事件的43项研究。
  • 药物警戒研究使用美国食品药品监督管理局不良事件报告系统(FAERS)数据补充分析。

主要发现

  • 荟萃分析显示SMX-TMP相比其他抗生素皮疹风险接近3倍(合并风险比2.56,95%CI 1.69-3.89,I2=0%,n=4458参与者,24项随机对照试验)。
  • 药物警戒数据显示SMX-TMP相比阿奇霉素,Stevens-Johnson综合征报告增加5倍,中毒性表皮坏死松解症增加3倍,伴嗜酸性粒细胞增多和系统症状的药疹增加10倍。
  • 药物警戒数据还显示SMX-TMP全血细胞减少报告增加10倍,中性粒细胞减少增加6倍,血小板减少和再生障碍性贫血各增加4倍,高钾血症增加56倍,低钠血症增加10倍。

临床怎么用

  • 门诊成人处方SMX-TMP时应关注皮疹等皮肤不良反应风险,并权衡其他抗生素选择。
  • 使用SMX-TMP期间需警惕血液系统异常及电解质紊乱(如高钾血症、低钠血症)相关表现。

局限性

  • 药物警戒分析基于自发报告数据,可能存在报告偏倚且无法确定因果关系。
  • 作者指出需进一步稳健研究确认这些安全信号并指导临床实践。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

AIMS: Sulfamethoxazole-trimethoprim (SMX-TMP) is a widely used antibiotic for treating bacterial infections, but its safety in adult outpatients remains understudied. This systematic review and meta-analysis evaluated the safety profile of SMX-TMP and identified critical research gaps. The pharmacovigilance study aimed to validate and extend findings from meta-analyses to better understand the real-world safety of SMX-TMP. METHODS: We searched MEDLINE and Embase up to 12 August 2024, to identify studies comparing adverse drug events (ADEs) following SMX-TMP vs. other antibiotics in adult outpatients. Meta-analyses were performed where data allowed. A pharmacovigilance study using the Food and Drug Administration Adverse Event Reporting System was conducted to supplement our findings. RESULTS: Our review, which included 43 studies, found SMX-TMP had a nearly 3-fold higher risk of rash compared to other antibiotics (pooled risk ratio 2.56, 95% confidence interval [1.69, 3.89], I2 = 0%, n = 4458 participants, 24 randomized control trials). Pharmacovigilance data confirmed a higher frequencies of skin disorders and other ADEs compared to various comparator drugs. Compared to azithromycin, SMX-TMP was associated with a 5-fold increase in Stevens-Johnson syndrome, a 3-fold increase in toxic epidermal necrolysis, and a 10-fold increase in drug reaction with eosinophilia and systemic symptoms. Additionally, SMX-TMP showed a 10-fold increase in reports of pancytopenia, a 6-fold increase in neutropenia, a 4-fold increase in both thrombocytopenia and aplastic anaemia, a 56-fold increase in hyperkalaemia, and a 10-fold increase in hyponatraemia. CONCLUSION: Our meta-analyses and pharmacovigilance study suggested SMX-TMP was associated with increased risk of ADEs compared to other antibiotics including amoxicillin/clavulanate, azithromycin and nitrofurantoin. Further robust research is essential to confirm these safety signals and guide clinical practice.

来源:Br J Clin Pharmacol,查看原文。版权归原作者所有。

引用

  1. Preyra R, Eddin LE, Ahmadi F, et al. Safety of sulfamethoxazole-trimethoprim for the treatment of bacterial infection in outpatient settings: A systematic review and meta-analysis with active comparator disproportionality analysis. Br J Clin Pharmacol. 2025. PMID: 40129122. doi:10.1002/bcp.70051

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。